Qiagen plans to expand its portfolio for QIAstat-Dx in the US to include a meningitis/encephalitis panel and a gastrointestinal panel, which is currently being reviewed by the US FDA. Image Credit: T. Schneider / Shutterstock.

The US Food and Drug Administration (FDA) has cleared Qiagen’s QIAstat-Dx Respiratory Panel Plus syndromic test, designed for pathogen detection in patients with upper respiratory infections.

The Netherlands-based company’s rapid panel covers 21 viral and bacterial targets which can cause upper respiratory infections and can give out results in about one hour. QIAstat-Dx panel was previously awarded emergency use authorisation (EUA) from the US FDA as QIAstat-Dx Respiratory SARS-CoV-2 Panel, in 2020.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The QIAstat-Dx panel can potentially improve the detection of co-infections, thereby, reducing the need for additional testing. The panel is available in two formats, a QIAstat-Dx Analyzer version that can integrate with up to four analytical modules and QIAstat-Dx Analyzer Rise, a higher-capacity version version capable of conducting 160 tests per day using eight analytical modules.

The company also plans to expand its portfolio for QIAstat-Dx in the US to include a meningitis and encephalitis panel, as well as a gastrointestinal panel, which is currently being reviewed by the US FDA.

Usual pathogen testing takes multiple days with rapid testing decreasing the analysis time. Multiple companies are developing rapid testing for diagnosing infection, with some even developing at-home tests to increase ease of use.

In February, Nexsen Biotech received grants totalling AU$5.5m ($3.56m) from the Australian Federal Government and Australia-based RMIT University support for the clinical development of a rapid point-of-care test, StrepSure. The test will diagnose the presence of Group B streptococci (GBS), which can cause serious infections in pregnant women, young babies, immunocompromised patients, and the elderly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In September 2023, Glasgow-based diagnostics spinout Microplate Dx raised £2.5m ($3.1m) in seed funding to develop a point-of-care device to identify effective antibiotics for bacterial infections. The device would allow for the confirmation of bacterial presence in the sample and perform rapid antibiotic susceptibility testing to identify the effective antibiotic. The company plans to first develop the device for urinary tract infections (UTIs).

Last week, Qiagen partnered with the US Federal Bureau of Investigation (FBI) to develop a novel digital PCR assay capable of detecting and quantifying minimal amounts of DNA with high accuracy for forensic use.